Suchergebnisse - "Hoekman, Jarno"

PubPharm (58)

1

Four scenarios for the future of medicines and social policy in 2030

enthalten in: Drug discovery today | 2022

von Leufkens, H. | Kusynová, Z. | Aitken, M. | +4

2

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

enthalten in: International journal of health policy and management | 2022

von Vreman, R. | Bloem, L. | van Oirschot, S. | +6

3

Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe : A comparison with standard approved cancer drugs

enthalten in: British journal of clinical pharmacology | 2022

von Bloem, L. | Bot, R. | Mantel-Teeuwisse, A. | +5

4

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Ten Ham, R. | Frederix, G. | Wu, O. | +4

5

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe : A comparison with standard approved cancer drugs

enthalten in: British Journal of Clinical Pharmacology | 2022

von Bloem, L. | Bot, R. | Mantel‐Teeuwisse, A. | +5

6

Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks

enthalten in: Expert opinion on drug safety | 2021

von Bloem, L. | Karomi, M. | Hoekman, J. | +4

7

Signals from the Dutch national spontaneous reporting system : Characteristics and regulatory actions

enthalten in: Pharmacoepidemiology and drug safety | 2021

von van Hunsel, F. | de Jong, E. | Gross-Martirosyan, L. | +1

8

Estimation of manufacturing development costs of cell-based therapies : a feasibility study

enthalten in: Cytotherapy | 2021

von Ten Ham, R. | Nievaart, J. | Hoekman, J. | +8

9

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

enthalten in: Clinical and translational science | 2021

von Bloem, L. | Vreman, R. | Peeters, N. | +6

10

Regulatory Safety Learning Driven by the Mechanism of Action : The Case of TNF-α Inhibitors

enthalten in: Clinical pharmacology and therapeutics | 2021

von Minnema, L. | Giezen, T. | Hoekman, J. | +3

1
2
3
4
5
6
Nächster »
[6]